Hospitals Face Profit Squeeze As Policy Risks Grow: Analyst
BofA warns hospitals face profit and volume pressure from policy cuts, favors post-acute care, upgrades Brookdale, and sees select names better positioned to weather challenges.
Stephens & Co. Maintains Overweight on Encompass Health, Maintains $70 Price Target
Stephens & Co. analyst Scott Fidel maintains Encompass Health (NYSE:EHC) with a Overweight and maintains $70 price target.
Earnings Scheduled For February 7, 2023
Companies Reporting Before The Bell
• BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.
Encompass Health Announces Plans To Build 50-Bed Inpatient Rehabilitation Hospital In Daytona Beach, Florida
Encompass Health Corp. (NYSE:EHC) today announced it plans to build a freestanding, 50-bed inpatient rehabilitation hospital in Daytona Beach, Florida. The hospital will be located at the southwest corner of
Stephens & Co. Maintains Overweight on Encompass Health, Lowers Price Target to $58
Stephens & Co. analyst Scott Fidel maintains Encompass Health (NYSE:EHC) with a Overweight and lowers the price target from $60 to $58.
Encompass Health Q3 EPS $0.67 Beats $0.64 Estimate, Sales $1.09B Beat $1.07B Estimate
Encompass Health (NYSE:EHC) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.64 by 4.69 percent. This is a 34.95 percent decrease over earnings of $1.03 per share from the
Bearish Sentiment Across The Cannabis Space – Check Full Movers For October 21, 2022
GAINERS:
Cannabix Technologies (OTC:BLOZF) shares closed up 7.71% at $0.37
Marijuana Stock Movers For October 12, 2022
GAINERS:
Charlottes Web Holdings (OTC:CWBHF) shares closed up 44.00% at $0.72
6 Analysts Have This to Say About Encompass Health
Encompass Health (NYSE:EHC) has observed the following analyst ratings within the last quarter:
Credit Suisse Maintains Outperform on Encompass Health, Lowers Price Target to $62
Credit Suisse analyst A.J. Rice maintains Encompass Health (NYSE:EHC) with a Outperform and lowers the price target from $63 to $62.